| Literature DB >> 34262469 |
Xiao-Hong Wei1,2,3,4,5,6, Xiao Guo1,2,3,4,5,6, Chun-Shui Pan2,3,4,5,6, Huan Li1,2,3,4,5,6, Yuan-Chen Cui2,3,4,5,6, Li Yan2,3,4,5,6, Jing-Yu Fan2,5,6, Jing-Na Deng2,3,4,5,6, Bai-He Hu2,3,4,5,6, Xin Chang2,3,4,5,6, Shu-Ya He1,2,3,4,5,6, Lu-Lu Yan2,3,4,5,6, Kai Sun2,3,4,5,6, Chuan-She Wang1,2,3,4,5,6, Jing-Yan Han1,2,3,4,5,6.
Abstract
BACKGROUND: T89, a traditional Chinese medicine, has passed phase II, and is undergoing phase III clinical trials for treatment of ischemic cardiovascular disease by the US FDA. However, the role of T89 on isoproterenol (ISO)-induced cardiac injury is unknown. The present study aimed to explore the effect and underlying mechanism of T89 on ISO-induced cardiac injury.Entities:
Keywords: cardiac hypertrophy; energy metabolism; fatty acid oxidation; glycolysis; mitochondrial electron transport chain
Year: 2021 PMID: 34262469 PMCID: PMC8273540 DOI: 10.3389/fphys.2021.653349
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Effects of T89 on survival rate, MBF, and heart function in rats exposed to ISO. (A) The survival curve of each group. (B) Representative color images of MBF in different groups acquired by Laser-Doppler Perfusion Imager. b1: Sham; b2: Sham + T89 167.4; b3: ISO; b4: ISO + T89 111.6; b5: ISO + T89 167.4. (C) Quantitative evaluation of MBF, n = 12. (D) Presented are the value of HR (d1), LVSP (d2), +dp/dt max (d3), LVDP (d4), LVEDP (d5), and -dp/dt max (d6) in various groups, n = 6. Data are presented as mean ± SE. *P < 0.05 vs. Sham group, #P < 0.05 vs. ISO group.
FIGURE 2Effect of T89 on myocardial histology, ultrastructure, and myocardial injury after ISO. (A) Representative HE-stained images in Sham (A1, A6), Sham + T89 167.4 group (A2, A7), ISO (A3, A8), ISO + T89 111.6 (A4, A9), and ISO + T89 167.4 (A5, A10). The upper panel was acquired at ×10 magnification of objective, and the lower panel was captured at ×20 magnification of objective. Bar = 100 μm. (B) Representative images of myocardial ultrastructure in Sham (B1), Sham + T89 167.4 group (B2), ISO (B3), ISO + T89 111.6 (B4), and ISO + T89 167.4 (B5). (C–E) The alteration of CK MB (C, n = 6) and cTnI (D, n = 6) content in plasma, and ANP content (E, n = 12) in the left ventricle. *P < 0.05 vs. Sham group, #P < 0.05 vs. ISO group.
FIGURE 3TMT-proteomics analysis of ISO group compared with the Sham group. (A) The Volcano Plot of differentially expressed proteins (DEPs) identified between ISO group and Sham group. Red dots represent upregulated DEPs; green dots represent downregulated DEPs; black dots represent unchanged proteins. (B) The top 30 significantly enriched GO terms for the DEPs identified between ISO group and Sham group using biological process, cellular component, and molecular function. (C) Statistics of pathway enrichment for the DEPs identified between ISO group and Sham group. (D) Classification of the enriched KEGG pathways for the DEPs identified between ISO group and Sham group.
FIGURE 4TMT-proteomics analysis of ISO + T89 group compared with the ISO group. (A) Statistics of pathway enrichment for the DEPs identified between ISO + T89 group and ISO group. (B) The heat map of DEPs altered in Sham, ISO and ISO + T89 group.
The altered proteins enriched in carbohydrate metabolism pathways evoked by ISO.
| Carbohydrate metabolism pathways | Altered proteins (ISO vs. Sham) | Up or down |
| Glycolysis | Eno1, Eno2, Eno3, Pfkp, Hk1, Hk2 | Up |
| Pentose phosphate pathway | G6pd, Tkt, Pfkp | Up |
| Citrate cycle | Mdh1, Suclg1, Suclg2, Idh1, Idh2 | Down |
| Glyoxylate and dicarboxylate metabolism | Cat, Mut, Mdh1, Pgp, Pcca, Acat1 | Down |
| Pentose and glucuronate interconversions | Akr1b10, Akr1b1, Sord, Dcxr | Down |
| Pyruvate metabolism | Mdh1, Aldh9a1, Glo1, Acyp2, Ldhd, Acat1 | Down |
| Galactose metabolism | Gaa, Galt, Akr1b1, Akr1b10 | Down |
| Glycerolipid metabolism | Akr1b10, Aldh9a1, Akr1b1 | Down |
| Fructose and mannose metabolism | Akr1b10, Akr1b1, Sord | Down |
| Gluconeogenesis | Aldh9a1, Adh5 | Down |
| Starch and sucrose metabolism | Gaa, Pygb | Down |
FIGURE 5Effect of T89 on ISO-induced alteration in metabolism and mitochondrial function. (A,B) Representative Western blotting bands and quantitative analysis of Eno1, Mcee, Bdh1, Ces1c, and Cbr4 in various groups. n = 4. (C,D) The content of pyruvic acid (C) and 3-HYA (D) in left ventricles in different groups. n = 6. (E,F) Representative Western blotting bands and quantitative analysis of ND2, Cox6a, Cox17, and ATP5j in various groups. n = 4. (G) The activity of complex I, IV, and V in left ventricles. n = 6. (H,I) The level of TBARS (H), and the ratio of ATP/AMP (I) in left ventricles. n = 6. *P < 0.05 vs. Sham group, #P < 0.05 vs. ISO group.
The altered proteins enriched in lipid metabolism pathways evoked by ISO.
| Lipid metabolism pathways | Altered proteins (ISO vs. Sham) | Up or down |
| Triglycerides metabolism | Agpat3, Ppt1, Lclat1, Ces1c | Up |
| Arachidonic acid metabolism | Ptgis | Up |
| Short-chain fatty acid catabolism | Mcee | Up |
| Synthesis and degradation of ketone bodies | Bdh1 | Up |
| Long chain omega-hydroxy fatty acids oxidation | Adh4 | Down |
| Lipid digestion, mobilization and transport | Fabp3, Apoc2, Lp1, Gpcpd1 | Down |
| Fatty acyl-CoA biosynthesis | Acsf2, Acsl1, Tecr, Cbr4, Gcdh | Down |
| Mitochondrial fatty acid β-oxidation | Acaa2, Acat1, Decr1, Eci1, Echs1, Gcdh, Hadh, Hadhb | Down |
FIGURE 6Effect of T89 on ISO-induced alteration in HSP70, HSP40, ERK 1/2, and CX43. (A–C) Western blotting validation of HSP70, HSP40, and corresponding quantitative evaluation in different groups. n = 4. (D–F) Representative Western blotting bands of P-ERK1/2, ERK 1/2, and the quantitative evaluation in different groups. n = 4. (G,H) Representative Western blotting bands and the quantitative analysis of CX43 in different groups. n = 4. *P < 0.05 vs. Sham group, #P < 0.05 vs. ISO group.
FIGURE 7Effect of T89 on ISO-induced cardiac hypertrophy. (A) Representative images of immunofluorescent staining of WGA and CX 43 in Sham (A1), Sham + T89 167.4 group (A2), ISO (A3), ISO + T89 111.6 (A4), and ISO + T89 167.4 (A5) groups. WGA is stained red, CX 43 is stained green, and nucleus blue. Bar = 50 μm. (B) Quantitative analysis of cardiomyocyte cross-section area. n = 4. (C) The ratio of HW/BW in each group. n = 11. *P < 0.05 vs. Sham group, #P < 0.05 vs. ISO group.
FIGURE 8A diagrammatic sketch showing the pathways that lead to the protected effects of T89 on ISO-induced cardiac injury. ISO causes enhancement of glycolysis and reduction of fatty acid metabolism and oxidative phosphorylation, resulting in energy disorder and oxidative stress with myocardial injury and reduction of MBF. Meanwhile, ISO-educed cardiac hypertrophy via regulating HSP70-ERK1/2 signals, which, together with cardiac injury, finally caused reduction of heart function and low survival rate. Nevertheless, T89 administration reversed all the above alteration. The cardioprotective role of T89 depended on the regulation of glycolipid metabolism, recovery of mitochondrial function, and improvement of myocardial energy.